Clinical trial · Interventional
18F-FES PET/CT in Imaging Patients With Desmoid Tumors
Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PI left institution
Summary
Brief summary (as posted)
This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors. 18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may show where tumor cells with estrogen receptors can be found in the body.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Deep Fibromatosis/Desmoid Tumor | Desmoid Fibromatosis | ALIAS | 0.90 |
| Familial Adenomatous Polyposis | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed Tomography | Procedure | — | UNRESOLVED |
| F-18 16 Alpha-Fluoroestradiol | Drug | — | UNRESOLVED |
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
| Positron Emission Tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (18F-FES PET/CT)
- description
- Patients undergo 18F-FES PET/CT imaging over 30 minutes.
- interventionNames
- Drug: F-18 16 Alpha-Fluoroestradiol
- Procedure: Positron Emission Tomography
- Procedure: Computed Tomography
- Other: Laboratory Biomarker Analysis
Primary outcomes (1)
- measure
- Standard uptake value (SUV) measured as percent injected dose per cc
- timeFrame
- Initial visit, average within 24 hours of imaging
- description
- Data will be summarized graphically and numerically. Continuous variables (e.g. SUV) will be summarized using the mean, standard deviation, and a 5 number percentile summary set (minimum, p25, p50, p75, and maximum). The Spearman correlation statistic will be used to estimate the magnitude of a linear association between SUV and IHC measures. Ninety-five percent confidence intervals will be calculated for all point estimates.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with biopsy-proven extra-abdominal desmoid tumors * Not currently on estrogen medication for birth control, menopause, or other reason * No anti-estrogen therapy for desmoid tumor within the past 6 months * Both sporadic desmoid tumors and those associated with familial adenomatous polyposis (FAP) syndromes will be included Exclusion Criteria: * Pregnancy or nursing patients * Patients who do not wish to participate
References
Publications (0)
Data not yet available